The Lawxy Times

DOJ Secures $13M Quest Diagnostics Settlement, Tightening Anti‑Kickback Enforcement

On November 9, 2026 the U.S. Department of Justice announced a $13 million settlement with Quest Diagnostics Inc. to resolve allegations of false claims submitted to Medicare and to the Medicaid programs of New York and New Jersey. The agreement clarifies that referral‑based remuneration linked to federal health‑care reimbursements will be treated as a false‑claims violation under existing statutes. Diagnostic laboratories and their referral partners must now align billing and contracting practices with the anti‑kickback and false‑claims frameworks. The settlement also signals that the government will pursue monetary penalties even where intent is disputed.

Full News Breakdown

The dispute originated from alleged payments and promotional benefits provided to the New York Football Giants in exchange for patient referrals to Quest’s laboratories, prompting federal prosecutors to allege false‑claims violations. Quest contended that any improper conduct was inadvertent, while the government emphasized the link between the referrals and the submitted claims. The parties resolved the matter through a monetary settlement without any admission of wrongdoing.

  • Case Name: United States v. Quest Diagnostics Inc.

  • Court: U.S. District Court for the District of New Jersey

  • Date: November 9, 2026

  • Statutes Cited: Federal False Claims Act, 31 U.S.C. §§ 3729‑3733; Anti‑Kickback Statute, 42 U.S.C. § 1320a‑7b

  • Key Provisions: FCA § 3729(a); Anti‑Kickback § 1320a‑7b(b)(1)

  • Primary Legal Issue: Whether referral arrangements constitute illegal kickbacks that render Medicare and Medicaid claims false

  • Petitioner/Plaintiff Arguments: Government alleged that Quest provided benefits to the Giants to secure referrals, thereby causing false claims to be submitted to federal and state health programs

  • Respondent/Defendant Arguments: Quest argued lack of specific intent and asserted that the referrals were legitimate business activities

  • Holding: Settlement reached; no admission of liability

  • Operative Order: Quest to pay $13 million to the United States Treasury

  • Practical Outcome: Enforcement emphasis on kickback risk in the diagnostic‑lab sector

How Does This Affect You?

Before this settlement, practitioners were uncertain how aggressively the DOJ would pursue false‑claims actions tied to referral incentives in the laboratory industry. The agreement resolves that the government will treat such remuneration schemes as false‑claims violations even when intent is not expressly proven. Consequently, entities must now treat any compensation linked to Medicare or Medicaid referrals as a direct enforcement risk, prompting a shift toward stricter compliance controls. This new certainty informs the guidance that follows for lawyers, students, and businesses.

For Lawyers & Advocates

  • Conduct a comprehensive audit of all laboratory‑referral agreements, focusing on clauses that tie payment to the volume or value of Medicare or Medicaid claims, because such language now triggers FCA liability.

  • Revise billing manuals to include a certification statement that each claim is for medically necessary services and is not influenced by any remuneration, referencing FCA § 3729(a) and the anti‑kickback safe‑harbor provisions.

  • Implement a “kickback safe‑harbor” policy under 42 U.S.C. § 1320a‑7b(b)(1) that requires pre‑approval of any marketing, sponsorship, or ticket‑exchange arrangement with health‑care providers.

  • In pending FCA qui tam actions, file a Rule 26(f) meet‑and‑confer brief that emphasizes the government’s heightened enforcement posture, to negotiate early settlements or carve‑outs that reflect the new risk calculus.

  • Advise clients to consider voluntary self‑disclosure under the DOJ Corporate Enforcement Policy, preserving communications and mitigating potential penalties for past periods that may now be deemed false claims.

For Law Students

The case demonstrates that courts will treat referral‑based remuneration as a false‑claims violation even when the defendant disputes specific intent. The core doctrinal focus is the interaction between the False Claims Act’s “knowing” requirement and the Anti‑Kickback Statute’s safe‑harbor analysis.
The decision is particularly relevant for the study of:

  • Federal health‑care fraud enforcement

  • The False Claims Act and its scienter standard

  • The Anti‑Kickback Statute and statutory safe harbors

  • Corporate compliance and self‑disclosure regimes

  • Governmental civil monetary penalties in health‑care contexts
    Comparable cases include United States v. McKesson Corp., 2013 (E.D. Va.) and United States v. Humana Inc., 2014 (E.D. Va.). Comparing those judgments with this settlement clarifies how courts balance intent, remuneration, and the statutory elements of false‑claims liability.

For Businesses

  • Diagnostic laboratories must amend provider contracts to insert a compliance certification clause affirming that no remuneration is tied to Medicare or Medicaid referrals, or risk CMS audit and recoupment.

  • Hospital CFOs should institute quarterly reviews of all external lab referral arrangements and obtain board approval for any sponsorship or ticket‑exchange agreements that could be viewed as remuneration.

  • Health‑insurance payers need to embed audit rights for lab‑provider referrals in their provider agreements to shield themselves from downstream false‑claims exposure.

  • Medical device manufacturers that bundle diagnostic services with equipment should reassess bundled pricing structures to ensure they do not create indirect kickback incentives linked to federal reimbursements.

Key Takeaways

  • The settlement establishes that any arrangement linking payment to Medicare or Medicaid referrals satisfies the elements of a false‑claims violation under the FCA and the Anti‑Kickback Statute.

  • Compliance officers must embed explicit anti‑kickback language and certification statements into billing policies, referral contracts, and marketing agreements.

  • The DOJ can now impose civil penalties without proving specific intent, focusing instead on the existence of false claims tied to prohibited remuneration.

  • Monitor the CMS “Referral Relationship Reporting” rule expected in early 2027, which may require public disclosure of lab‑provider agreements and additional documentation.

  • In‑house counsel should complete a full contract audit of all lab‑referral agreements before the March 31, 2027 fiscal‑year‑end reporting deadline to avoid exposure.

Source: Quest Pays $13M To End Giants Ticket Kickback Claims

Author Image
Lawxy Times Reporter

DOJ Secures $13M Quest Diagnostics Settlement, Tightening Anti‑Kickback Enforcement

Secure by design. Built for enterprise.

More About Security

Lawxy AI is designed with encrypted infrastructure, access controls, audit visibility, and enterprise-grade security standards.

SOC 2 Type I, II

GDPR

ISO 27001

VAPT Tested

See Legal Intelligence in Action?

LAWXY

Legal Intelligence Layer Businesses Rely On

Copyright© 2026 Lawxy AI. All Rights Reserved.

Secure by design. Built for enterprise.

More About Security

Lawxy AI is designed with encrypted infrastructure, access controls, audit visibility, and enterprise-grade security standards.

SOC 2 Type I, II

GDPR

ISO 27001

VAPT Tested

See Legal Intelligence in Action?

LAWXY

Legal Intelligence Layer Businesses Rely On

Copyright© 2026 Lawxy AI. All Rights Reserved.

Secure by design. Built for enterprise.

More About Security

Lawxy AI is designed with encrypted infrastructure, access controls, audit visibility, and enterprise-grade security standards.

SOC 2 Type I, II

GDPR

ISO 27001

VAPT Tested

See Legal Intelligence in Action?

LAWXY

Legal Intelligence Layer Businesses Rely On

Copyright© 2026 Lawxy AI. All Rights Reserved.